JP7393766B2 - 抗体回避ウイルスベクターのための方法および組成物 - Google Patents
抗体回避ウイルスベクターのための方法および組成物 Download PDFInfo
- Publication number
- JP7393766B2 JP7393766B2 JP2020545088A JP2020545088A JP7393766B2 JP 7393766 B2 JP7393766 B2 JP 7393766B2 JP 2020545088 A JP2020545088 A JP 2020545088A JP 2020545088 A JP2020545088 A JP 2020545088A JP 7393766 B2 JP7393766 B2 JP 7393766B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- aav
- amino acid
- capsid
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013603 viral vector Substances 0.000 title claims description 168
- 238000000034 method Methods 0.000 title claims description 119
- 239000000203 mixture Substances 0.000 title claims description 38
- 108090000565 Capsid Proteins Proteins 0.000 claims description 282
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 280
- 210000000234 capsid Anatomy 0.000 claims description 229
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 204
- 239000002245 particle Substances 0.000 claims description 156
- 150000007523 nucleic acids Chemical class 0.000 claims description 146
- 102000039446 nucleic acids Human genes 0.000 claims description 132
- 108020004707 nucleic acids Proteins 0.000 claims description 132
- 238000006467 substitution reaction Methods 0.000 claims description 115
- 108090000623 proteins and genes Proteins 0.000 claims description 91
- 241000700605 Viruses Species 0.000 claims description 51
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 241000702421 Dependoparvovirus Species 0.000 claims description 23
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 description 228
- 210000004027 cell Anatomy 0.000 description 162
- 150000001413 amino acids Chemical class 0.000 description 104
- 229940024606 amino acid Drugs 0.000 description 101
- 239000013598 vector Substances 0.000 description 99
- 108090000765 processed proteins & peptides Proteins 0.000 description 96
- 230000003612 virological effect Effects 0.000 description 94
- 102000004196 processed proteins & peptides Human genes 0.000 description 83
- 229920001184 polypeptide Polymers 0.000 description 74
- 206010028980 Neoplasm Diseases 0.000 description 64
- 230000003472 neutralizing effect Effects 0.000 description 64
- 238000010361 transduction Methods 0.000 description 53
- 239000000427 antigen Substances 0.000 description 52
- 230000026683 transduction Effects 0.000 description 52
- 108091007433 antigens Proteins 0.000 description 50
- 102000036639 antigens Human genes 0.000 description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 43
- 201000011510 cancer Diseases 0.000 description 40
- 230000014509 gene expression Effects 0.000 description 38
- 210000003205 muscle Anatomy 0.000 description 38
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 35
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 34
- 201000010099 disease Diseases 0.000 description 33
- 230000002163 immunogen Effects 0.000 description 32
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 27
- 230000004048 modification Effects 0.000 description 27
- 238000012986 modification Methods 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 25
- 241000125945 Protoparvovirus Species 0.000 description 24
- 238000012384 transportation and delivery Methods 0.000 description 24
- 230000028993 immune response Effects 0.000 description 23
- 210000002027 skeletal muscle Anatomy 0.000 description 21
- 230000010415 tropism Effects 0.000 description 21
- 241000701161 unidentified adenovirus Species 0.000 description 20
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 19
- 108091030071 RNAI Proteins 0.000 description 19
- 230000009368 gene silencing by RNA Effects 0.000 description 19
- -1 gonadoliverin Chemical compound 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 230000001939 inductive effect Effects 0.000 description 16
- 238000004806 packaging method and process Methods 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 230000008685 targeting Effects 0.000 description 16
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 238000003780 insertion Methods 0.000 description 15
- 230000037431 insertion Effects 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 101710163270 Nuclease Proteins 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000013607 AAV vector Substances 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 13
- 101710081079 Minor spike protein H Proteins 0.000 description 13
- 230000000890 antigenic effect Effects 0.000 description 13
- 210000003169 central nervous system Anatomy 0.000 description 13
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 238000001415 gene therapy Methods 0.000 description 13
- 230000000670 limiting effect Effects 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 11
- 108010056852 Myostatin Proteins 0.000 description 11
- 230000000747 cardiac effect Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 210000004165 myocardium Anatomy 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 230000009257 reactivity Effects 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 241001529453 unidentified herpesvirus Species 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 10
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 101150044789 Cap gene Proteins 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 210000004408 hybridoma Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- 230000002463 transducing effect Effects 0.000 description 9
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 8
- 229920002971 Heparan sulfate Polymers 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 description 8
- 241000713311 Simian immunodeficiency virus Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229910052731 fluorine Inorganic materials 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 108010059929 phospholamban Proteins 0.000 description 8
- 230000001603 reducing effect Effects 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 102000004627 Iduronidase Human genes 0.000 description 7
- 108010003381 Iduronidase Proteins 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 241000700584 Simplexvirus Species 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 101150066583 rep gene Proteins 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 229910052721 tungsten Inorganic materials 0.000 description 7
- 241000649046 Adeno-associated virus 11 Species 0.000 description 6
- 102100022641 Coagulation factor IX Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000007072 Nerve Growth Factors Human genes 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 238000009126 molecular therapy Methods 0.000 description 6
- 239000003900 neurotrophic factor Substances 0.000 description 6
- 102000005681 phospholamban Human genes 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241000649045 Adeno-associated virus 10 Species 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 108010054218 Factor VIII Proteins 0.000 description 5
- 102000001690 Factor VIII Human genes 0.000 description 5
- 208000015872 Gaucher disease Diseases 0.000 description 5
- 102000004547 Glucosylceramidase Human genes 0.000 description 5
- 108010017544 Glucosylceramidase Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101710096786 Lysosomal acid alpha-glucosidase Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 102000006308 Sarcoglycans Human genes 0.000 description 5
- 108010083379 Sarcoglycans Proteins 0.000 description 5
- 108010030291 alpha-Galactosidase Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000000188 diaphragm Anatomy 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 229960000301 factor viii Drugs 0.000 description 5
- 238000001476 gene delivery Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
- 239000013608 rAAV vector Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 102400000068 Angiostatin Human genes 0.000 description 4
- 108010079709 Angiostatins Proteins 0.000 description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
- 102100026189 Beta-galactosidase Human genes 0.000 description 4
- 241000701931 Canine parvovirus Species 0.000 description 4
- 108010069091 Dystrophin Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102400001047 Endostatin Human genes 0.000 description 4
- 108010079505 Endostatins Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000024720 Fabry Disease Diseases 0.000 description 4
- 108010076282 Factor IX Proteins 0.000 description 4
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 4
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 208000015178 Hurler syndrome Diseases 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000019022 Mood disease Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000003679 cervix uteri Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001493 electron microscopy Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 229960004222 factor ix Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 201000004502 glycogen storage disease II Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 201000002273 mucopolysaccharidosis II Diseases 0.000 description 4
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 4
- 201000006938 muscular dystrophy Diseases 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 208000030613 peripheral artery disease Diseases 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000003314 quadriceps muscle Anatomy 0.000 description 4
- 239000013646 rAAV2 vector Substances 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010059616 Activins Proteins 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 3
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 3
- 241000649047 Adeno-associated virus 12 Species 0.000 description 3
- 241000958487 Adeno-associated virus 3B Species 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 102000001039 Dystrophin Human genes 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 102000016970 Follistatin Human genes 0.000 description 3
- 108010014612 Follistatin Proteins 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- 102000053187 Glucuronidase Human genes 0.000 description 3
- 108010060309 Glucuronidase Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101000685712 Homo sapiens Protein S100-A1 Proteins 0.000 description 3
- 208000015204 Hurler-Scheie syndrome Diseases 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 102000003996 Interferon-beta Human genes 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 102000000853 LDL receptors Human genes 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- 206010023927 Lassa fever Diseases 0.000 description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 3
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 3
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 3
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 3
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 description 3
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 102000001675 Parvalbumin Human genes 0.000 description 3
- 108060005874 Parvalbumin Proteins 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102100023097 Protein S100-A1 Human genes 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000411545 Punargentus Species 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 201000002883 Scheie syndrome Diseases 0.000 description 3
- 201000001828 Sly syndrome Diseases 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 102000005157 Somatostatin Human genes 0.000 description 3
- 108010056088 Somatostatin Proteins 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010075653 Utrophin Proteins 0.000 description 3
- 102000011856 Utrophin Human genes 0.000 description 3
- 239000000488 activin Substances 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 102000005840 alpha-Galactosidase Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 3
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 3
- 229940112869 bone morphogenetic protein Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 239000012470 diluted sample Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 208000007345 glycogen storage disease Diseases 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 3
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 3
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 3
- 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 description 3
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940037201 oris Drugs 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960000553 somatostatin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012385 systemic delivery Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 2
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 2
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 2
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- 208000017194 Affective disease Diseases 0.000 description 2
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102100031491 Arylsulfatase B Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 241000701922 Bovine parvovirus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 108010051834 CTTHWGFTLC peptide Proteins 0.000 description 2
- 208000022526 Canavan disease Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 101710197665 Capsid protein VP2 Proteins 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108091000069 Cystinyl Aminopeptidase Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101150066038 E4 gene Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 description 2
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 description 2
- 101800002068 Galanin Proteins 0.000 description 2
- 102400001370 Galanin Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 102000016871 Hexosaminidase A Human genes 0.000 description 2
- 108010053317 Hexosaminidase A Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 244000309467 Human Coronavirus Species 0.000 description 2
- 241000702617 Human parvovirus B19 Species 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- 108010053927 Iduronate Sulfatase Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 2
- 101710151321 Melanostatin Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 241000702623 Minute virus of mice Species 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 2
- 101710099863 N-acetylgalactosamine-6-sulfatase Proteins 0.000 description 2
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 description 2
- 108010023320 N-acetylglucosamine-6-sulfatase Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
- 102400000064 Neuropeptide Y Human genes 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 2
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108700005081 Overlapping Genes Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102000011265 Sarcospan Human genes 0.000 description 2
- 108050001531 Sarcospan Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 208000027520 Somatoform disease Diseases 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 102220564325 TIR domain-containing adapter molecule 2_S16E_mutation Human genes 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 108091026823 U7 small nuclear RNA Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 101710185494 Zinc finger protein Proteins 0.000 description 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108010014063 beta-adrenergic receptor kinase inhibitory peptide Proteins 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000015861 cell surface binding Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 108700020302 erbB-2 Genes Proteins 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 150000002298 globosides Chemical class 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 208000009429 hemophilia B Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 108091061970 miR-26a stem-loop Proteins 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 208000012253 mucopolysaccharidosis IVA Diseases 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MKSPBYRGLCNGRC-OEMOKZHXSA-N (2s)-2-[[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-aminopropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound O=C([C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)CC(C)C)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MKSPBYRGLCNGRC-OEMOKZHXSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- AGTSSZRZBSNTGQ-ITZCFHCWSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomet Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 AGTSSZRZBSNTGQ-ITZCFHCWSA-N 0.000 description 1
- KBSORCBSCSOBHH-IHJZLXGESA-N (4s)-5-[(2s)-2-[[(2s)-6-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin Chemical compound CC(C)[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KBSORCBSCSOBHH-IHJZLXGESA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 101800000504 3C-like protease Proteins 0.000 description 1
- BMNBFRJBYVIOAY-UHFFFAOYSA-N 4,7,8-trihydroxy-3,4-dihydro-2h-isoquinolin-2-ium-1-one;chloride Chemical compound [Cl-].OC1=CC=C2C(O)C[NH2+]C(=O)C2=C1O BMNBFRJBYVIOAY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- XQMVBICWFFHDNN-UHFFFAOYSA-N 5-amino-4-chloro-2-phenylpyridazin-3-one;(2-ethoxy-3,3-dimethyl-2h-1-benzofuran-5-yl) methanesulfonate Chemical compound O=C1C(Cl)=C(N)C=NN1C1=CC=CC=C1.C1=C(OS(C)(=O)=O)C=C2C(C)(C)C(OCC)OC2=C1 XQMVBICWFFHDNN-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 1
- 102100021305 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Human genes 0.000 description 1
- 241000300529 Adeno-associated virus 13 Species 0.000 description 1
- 241000425548 Adeno-associated virus 3A Species 0.000 description 1
- 102100032534 Adenosine kinase Human genes 0.000 description 1
- 108010076278 Adenosine kinase Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 241000702419 Ambidensovirus Species 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101150102415 Apob gene Proteins 0.000 description 1
- 101150094024 Apod gene Proteins 0.000 description 1
- 101150104773 Apoh gene Proteins 0.000 description 1
- 101800001976 Apolipoprotein B-48 Proteins 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 101100113633 Arabidopsis thaliana CKL9 gene Proteins 0.000 description 1
- 241000726096 Aratinga Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 108010088141 Argonaute Proteins Proteins 0.000 description 1
- 102100032948 Aspartoacylase Human genes 0.000 description 1
- 108700023155 Aspartoacylases Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102000007372 Ataxin-1 Human genes 0.000 description 1
- 108010032963 Ataxin-1 Proteins 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000124740 Bocaparvovirus Species 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102100035344 Cadherin-related family member 1 Human genes 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 101100342337 Caenorhabditis elegans klf-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101800001319 Capsid protein VP3 Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000000018 Chemokine CCL2 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000684559 Chicken parvovirus Species 0.000 description 1
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010456 Congenital emphysema Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 108700002856 Coronavirus Envelope Proteins Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102100024108 Dystrophin Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 102100038083 Endosialin Human genes 0.000 description 1
- 101710144543 Endosialin Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000121268 Erythroparvovirus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102100027186 Extracellular superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
- 108700001268 Extracellular superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000701925 Feline parvovirus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 102000003869 Frataxin Human genes 0.000 description 1
- 108090000217 Frataxin Proteins 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010033708 GFE-1 peptide Proteins 0.000 description 1
- 101150117028 GP gene Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 102100028496 Galactocerebrosidase Human genes 0.000 description 1
- 108010042681 Galactosylceramidase Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241001517118 Goose parvovirus Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000702620 H-1 parvovirus Species 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 101001042227 Homo sapiens Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000737767 Homo sapiens Cadherin-related family member 1 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101000652321 Homo sapiens Protein SOX-15 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000687911 Homo sapiens Transcription factor SOX-3 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000711450 Infectious bronchitis virus Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102400001355 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 108010010994 K237 peptide Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 101150072501 Klf2 gene Proteins 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282564 Macaca fuscata Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 208000030162 Maple syrup disease Diseases 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000489861 Maximus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108091092539 MiR-208 Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 description 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
- 102400001357 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 108091057508 Myc family Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150118742 NP gene Proteins 0.000 description 1
- 241000158526 Nasalis Species 0.000 description 1
- 102100028782 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- RMINQIRDFIBNLE-NNRWGFCXSA-N O-[N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosaminyl]-L-serine Chemical compound O1[C@H](OC[C@H](N)C(O)=O)[C@H](NC(=O)C)[C@@H](O)[C@@H](O)[C@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 RMINQIRDFIBNLE-NNRWGFCXSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 241000223503 Platysma Species 0.000 description 1
- 102100024266 Pneumadin Human genes 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 108010012809 Progranulins Proteins 0.000 description 1
- 102000019204 Progranulins Human genes 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
- 108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
- 102100030244 Protein SOX-15 Human genes 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 229940116193 Protein phosphatase inhibitor Drugs 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 102400000235 Rimorphin Human genes 0.000 description 1
- 101800001440 Rimorphin Proteins 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102400000821 Somatostatin-28 Human genes 0.000 description 1
- 101800004701 Somatostatin-28 Proteins 0.000 description 1
- 108010019965 Spectrin Proteins 0.000 description 1
- 102000005890 Spectrin Human genes 0.000 description 1
- 201000003622 Spinocerebellar ataxia type 2 Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 1
- 102100035000 Thymosin beta-4 Human genes 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091028113 Trans-activating crRNA Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102100024276 Transcription factor SOX-3 Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 102100021162 Tubulinyl-Tyr carboxypeptidase 2 Human genes 0.000 description 1
- 101710179228 Tubulinyl-Tyr carboxypeptidase 2 Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108091026838 U1 spliceosomal RNA Proteins 0.000 description 1
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
- 101100049199 Xenopus laevis vegt-a gene Proteins 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 101150065716 adk1 gene Proteins 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 238000002299 affinity electrophoresis Methods 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 238000010378 bimolecular fluorescence complementation Methods 0.000 description 1
- 238000012575 bio-layer interferometry Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940096384 chicken egg white lysozyme Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 206010010121 compartment syndrome Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 108010068597 corticostatin Proteins 0.000 description 1
- ZKALIGRYJXFMNS-XBDDSDALSA-N corticostatin Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(C)C)C(C)C)CC1=CC=CC=C1 ZKALIGRYJXFMNS-XBDDSDALSA-N 0.000 description 1
- 108010066070 cysteinyl-prolyl-isoleucyl-glutamyl-aspartyl-arginyl-prolyl-methionyl-cysteine (1-9) disulfide Proteins 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000000612 dual polarization interferometry Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000000647 epithalamus Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 108010046019 histidyl-glutamyl-tryptophyl-seryl-tyrosyl-leucyl-alanyl-prolyl-tyrosyl-prolyl-tryptophyl-phenylalanine Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 210000003552 inferior colliculi Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108700027921 interferon tau Proteins 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940118526 interleukin-9 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 108010075476 isoleucyl-glutamyl-leucyl-leucyl-glutaminyl-alanyl-arginine Proteins 0.000 description 1
- 238000000111 isothermal titration calorimetry Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010008097 laminin alpha 2 Proteins 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000024393 maple syrup urine disease Diseases 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 1
- 108091028606 miR-1 stem-loop Proteins 0.000 description 1
- 108091023685 miR-133 stem-loop Proteins 0.000 description 1
- 108091063796 miR-206 stem-loop Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 238000002439 negative-stain electron microscopy Methods 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 101800000607 p15 Proteins 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000000062 pectoralis major Anatomy 0.000 description 1
- 210000000989 pectoralis minor Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 108010012604 pneumadin Proteins 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 210000002176 pterygoid muscle Anatomy 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 230000007441 retrograde transport Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 101150005399 sod2 gene Proteins 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 229940038774 squalene oil Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001587 telencephalon Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 108010079996 thymosin beta(4) Proteins 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
本出願は、2018年6月20日提出の米国特許仮出願第62/687,583号、および2018年2月28日提出の米国特許仮出願第62/636,598号の、35U.S.C.§119(e)の下での利益を主張するものであり、前記特許文献の全内容は引用することにより本明細書の一部をなすものとする。
本発明は、米国国立衛生研究所により与えられる認可番号HL112761、GM082946、およびHL089221の下、政府出資で行われた。政府は、本発明にある特定の権利を有する。
ASCIIテキストフォーマットでの配列表は、37C.F.R.§1.821の下で提出され、表題は5470-838WO_ST25.txtと付けられ、サイズは223,970バイトで、2019年2月28日に作成され、EFS-Webを経て提出され、ハードコピーに代わって提供される。本配列表は、その開示のために引用することにより本明細書の一部をなすものとする。
本開示は、アデノ随伴ウイルス(AAV)由来の改変カプシドタンパク質ならびに前記同一カプシドタンパク質を含むウイルスカプシドおよびウイルスベクターに関する。特に、本開示は、改変AAVカプシドタンパク質およびウイルスベクター中に組み込んで、形質導入効率が減少せずに中和抗体を回避する表現型を与えることができる前記同一カプシドタンパク質を含むカプシドに関する。
以下の用語は、本明細書での説明および添付の特許請求の範囲において使用される。
Samulski et al.への米国特許第5,478,745号に記載される「二重D配列」などの、部分的または完全な合成が可能である。
本開示は、アミノ酸配列に改変(例えば、置換)を含むAAVカプシドタンパク質(VP1、VP2および/またはVP3)ならびに改変AAVカプシドタンパク質を含むウイルスカプシドおよびウイルスベクターを提供する。発明者らは、AAVカプシドタンパク質を改変すると改変AAVカプシドタンパク質を含むウイルスベクターに、限定せずに中和抗体を回避する能力を含む1つまたは複数の望ましい特性を与えることができることを発見していた。したがって、本開示は、従来のAAVベクターに関連する制限のいくつかに取り組む。
野生型AAVゲノムは一本鎖デオキシリボ核酸(ssDNA)であり、ポジティブまたはネガティブセンスである。ゲノムは、2つの逆位末端反復(ITR)、DNA鎖のそれぞれの末端に1つ、および2つのオープンリーディングフレーム(ORF)、ITR間にrepおよびcapを含む。rep ORFは、AAV生活環に必要なRepタンパク質をコードする4つのオーバーラップ遺伝子:Rep78、Rep68、Rep52およびRep40を含む。cap ORFはカプシドタンパク質:VP1、VP2およびVP3をコードするオーバーラップ遺伝子を含み、これらのカプシドタンパク質は互いに相互作用してウイルスカプシドを形成する。VP1、VP2およびVP3は2つの選択的にスプライスされた転写物から翻訳される。カプシドは60の個々のカプシドタンパク質サブユニットの超分子集合体を形成して、AAVゲノムを保護することができる無エンベロープのT-1正二十面体カプシドになる。集合したカプシドは、VP1、VP2およびVP3(分子質量はそれぞれおおよそ87、73、および62kDa)で約1対1対10の比で構成されている。
改変5回領域(a modified 5-fold region)を含むrAAVカプシドタンパク質が本明細書で提供される。改変は、例えば、置換、欠失、および/または挿入を含みうる。一部の実施形態では、改変5回領域は、1つまたは複数のアミノ酸置換(例えば、1、2、3、4、5、6、7、8、9、10またはそれよりも多いアミノ酸置換)を含む。一部の実施形態では、改変5回領域は、天然の配列と比べてDE-ループに1つまたは複数のアミノ酸置換を含む。一部の実施形態では、改変5回領域は、天然の配列と比べてHI-ループに1つまたは複数のアミノ酸置換を含む。一部の実施形態では、改変5回領域は、天然の配列と比べて2/5回ウォールに1つまたは複数のアミノ酸置換を含む。一部の実施形態では、改変5回領域は、DE-ループおよびHI-ループに1つまたは複数のアミノ酸置換を含む。一部の実施形態では、改変5回領域は、DE-ループおよび2/5回ウォールに1つまたは複数のアミノ酸置換を含む。一部の実施形態では、改変5回領域は、HI-ループおよび2/5回ウォールに1つまたは複数のアミノ酸置換を含む。一部の実施形態では、改変5回領域は、DE-ループ、HI-ループ、および2/5回ウォールに1つまたは複数のアミノ酸置換を含む。
一部の実施形態では、改変5回領域でのアミノ酸置換は、荷電アミノ酸(例えば、D、E、K、R、またはH)の非荷電または極性アミノ酸(例えば、A、N、C、Q、G、I、L、M、F、P、S、T、W、Y、またはV)での置換を含む。一部の実施形態では、改変5回領域でのアミノ酸置換は、非荷電または極性アミノ酸(例えば、A、N、C、Q、G、I、L、M、F、P、S、T、W、Y、V)の荷電アミノ酸(例えば、D、E、K、R、またはH)での置換を含む。
一実施形態では、本開示はウイルスベクターを作製する方法であって、(a)少なくとも1つのTR配列(例えば、AAV TR配列)を含む核酸鋳型、および(b)核酸鋳型の複製およびAAVカプシド中へのカプシド化に十分なAAV配列(例えば、AAVrep配列および本開示のAAVカプシドをコードするAAVcap配列)を細胞に提供することを含む方法を提供する。任意選択で、核酸鋳型は、少なくとも1つの異種核酸配列をさらに含む。特定の実施形態では、核酸鋳型は2つのAAV ITR配列を含み、これらの配列は異種核酸配列(存在する場合)の5’側および3’側に位置しているが、それに直接隣接する必要はない。
本開示のウイルスベクターは、インビトロ、エクスビボ、およびインビボでの核酸の細胞への送達に有用である。特に、ウイルスベクターは、哺乳動物を含む動物の細胞に核酸を送達するまたは移入するために都合よく用いることができる。
AAV粒子に結合することができインビボで細胞に感染するその能力を減らす抗体は「中和抗体」である。一部の実施形態では、中和抗体は自然に存在する。一部の実施形態では、中和抗体は、組換えrAAV粒子またはカプシドを対象(例えば、ウサギ、またはマウス)中に注入することにより発生させる。一部の実施形態では、中和抗体と投与されたrAAV粒子の間の相互作用により免疫応答が生じる。一部の実施形態では、中和抗体と投与されたrAAV粒子の間の相互作用により、細胞、組織、臓器、または対象を形質導入するrAAV粒子の効率を下げるので、抗体中和に起因する喪失を穴埋めするためにもっと高用量のrAAV粒子を対象に投与しなければならなくなる。
一部の実施形態では、AAVaについて血清陽性である対象に、本開示のカプシドタンパク質(例えば、アミノ酸配列X1-X2-T-F-N-X3-X4-K-L-X5(配列番号197)、アミノ酸配列X1-X2-T-F-N-X3-X4(配列番号198)を生じる置換を含むカプシドタンパク質および/または改変5回領域を含むカプシドタンパク質)を含むrAAV粒子を投与する方法は、対象が、投与されることになる血清型のAAVについて血清陽性であるかどうかを判定することをさらに含む。
一部の実施形態では、本明細書に開示されるように、本開示のカプシドタンパク質を含む(例えば、アミノ酸配列X1-X2-T-F-N-X3-X4-K-L-X5(配列番号197)、アミノ酸配列X1-X2-T-F-N-X3-X4(配列番号198)を生じる置換を含むおよび/または改変5回領域を含む)1つまたは複数のrAAV粒子を、rAAVを受けることになっているまたは受けたことがある対象に投与すれば、対照(例えば、アミノ酸配列X1-X2-T-F-N-X3-X4-K-L-X5(配列番号197)、アミノ酸配列X1-X2-T-F-N-X3-X4(配列番号198)を生じる置換のないおよび/または改変5回領域のないVPタンパク質を含むrAAV粒子)の投与と比べて、中和抗体に対する反応性の減少、または投与されたrAAVの形質導入効率の改善を生じる。一部の実施形態では、本明細書に開示される方法のいずれか1つは、本開示のカプシドタンパク質を含む1つまたは複数のrAAV粒子を、中和抗体に対する反応性の減少、またはインビボでのAAV形質導入効率の増加を生じる量で投与することを含む。
種々の血清型のrAAV粒子上で抗原フットプリントを作成する方法も本明細書で提供される。一部の実施形態では、特定のrAAV粒子上での特定の抗体についての抗原フットプリントを作成する方法は、ハイブリドーマ上澄み由来の抗体の精製(例えば、カラム精製を使用して)、精製抗体を酵素を使用して切断し、Fabを精製し、それをrAAV粒子またはウイルス様粒子(空のカプシド)と種々のモル比(例えば、60対1、70対1、80対1、90対1、100対1、11対1、120対1)で複合体化し、電子顕微鏡を使用して低温EMデータを収集し、複合体の個別の画像を分離し、単一粒子再構成を実施し、ウイルスカプシドの入手可能な結晶構造および一般的なFab構造を使用して再構成密度マップを解釈し、Fabとカプシドの間の相互作用している残基を視覚化することを含む。一部の実施形態では、カプシド-Fab構造の解像度は、Fabとカプシドの間の相互作用している残基を視覚化するのに十分高い。一部の実施形態では、低温EMを使用して作成されるフットプリントは変異誘発を使用して確認される。
本開示に従ったウイルスベクターおよびカプシドは、獣医と医学応用の両方において用途がある。適切な対象はトリと哺乳動物の両方を含む。本明細書で使用される用語「トリ」は、これらに限定されないが、ニワトリ、アヒル、ガチョウ、ウズラ、シチメンチョウ、キジ、オウム、インコ、および同類のものを含む。本明細書で使用される用語「哺乳動物」は、これらに限定されないが、ヒト、非ヒト霊長類、ウシ、ヒツジ、ヤギ、ウマ、ネコ、イヌ、ウサギ、等を含む。ヒト対象は、新生児、幼児、少年少女、成人および老人対象を含む。
抗体HL2372のフットプリントに無作為化された改変のある配列のライブラリーを作製し、複製可能AAV粒子を産生する能力についてスクリーニングし、DNAを適切に折り畳みも、組み立ても、パッケージもしないことがある存続不能な配列をふるい落とした。抗体HL2372による結合を回避することができる配列で、集合してゲノムパッケージング粒子になることができる配列を含む複製可能AAV突然変異体を選択し作製した。本明細書に開示される方法から同定され、抗体HL2372のフットプリントにおいて改変され、したがって、抗体HL2372による結合を回避することができる存続可能なカプシド配列は図1に示されている。下線を施された残基は、野生型AAV8配列(配列番号8)のその位置に適合している。突然変異した残基はP661、T662、Q666、S667、N670である。それぞれの位置で無作為化されたAAVカプシドライブラリーの選択に続いて進化された異なるアミノ酸残基は強調されている。突然変異した残基は、野生型AAV配列と比べて類似するウイルス粒子数を生じるように進化させた。
AAV8およびAAV9カプシドの発現および精製:組換えAAV8およびAAV9ウイルス様粒子(VLP)は、以前報告された通りに(Lane et al.2005;Mitchell et al.2009)、Bac-to-Bacバキュロウイルス-Sf9昆虫細胞発現系(Gibco/Invitrogen、Carlsbad、CA)を使用して発現させ、20%のスクロースクッション続いてスクロース勾配(5~40%[wt/vol])を使用して精製した。精製されたAAV8およびAAV9 VLPは、1~3mg/mlまで濃縮され、1×PBS、pH7.4中にバッファー交換した。試料の濃度は、光学密度測定(mg/mlでの計算ではOD280およびE=1.7を使用して)、ならびにBSA濃度標準のSDS-PAGEゲル電気泳動により評価した。使用に先立って、VLPの純度および完全性も、それぞれSDS-PAGEおよび陰性染色EMによりモニターした。
本明細書で開示される特長のすべてはいかなる組み合わせで組み合わせてもよい。本明細書で開示されるそれぞれの特長は、同じ、等価な、または類似する目的にかなう別の特長により置き換えてもよい。したがって、別段明白に述べられなければ、開示されるそれぞれの特長は一般的な一連の等価なまたは類似する特長の例にすぎない。
出願時の特許請求の範囲は、以下の通り。
[請求項1]
配列番号8として特定されるAAV8の参照アミノ酸配列に基づいて天然のAAV8カプシドタンパク質のアミノ酸位661~670(VP1番号付け)に対応し、配列番号26として特定されるAAV9の参照アミノ酸配列に基づいて天然のAAV9カプシドタンパク質のアミノ酸位659~668(VP1番号付け)に対応するアミノ酸に、または他の任意のAAV血清型のカプシドタンパク質における等価なアミノ酸位に、アミノ酸配列:X1-X2-T-F-N-X3-X4-K-L-X5(配列番号197)を生じる置換を含むアデノ随伴ウイルス(AAV)カプシドタンパク質であって、
X1はP以外の任意のアミノ酸であり;
X2はT以外の任意のアミノ酸であり;
X3はQ以外の任意のアミノ酸であり;
X4はS以外の任意のアミノ酸であり;および/または
X5はN以外の任意のアミノ酸である、
アデノ随伴ウイルス(AAV)カプシドタンパク質。
[請求項2]
X1がV、I、Q、S、F、R、またはWである、請求項1に記載のAAVカプシドタンパク質。
[請求項3]
X2がG、S、L、V、C、D、R、I、またはPである、請求項1または2のいずれか1項に記載のAAVカプシドタンパク質。
[請求項4]
X3がE、P、C、S、G、R、D、L、N、V、またはAである、請求項1~3のいずれか1項に記載のAAVカプシドタンパク質。
[請求項5]
X4がP、Q、G、R、D、C、A、M、H、またはTである、請求項1~4のいずれか1項に記載のAAVカプシドタンパク質。
[請求項6]
X5がH、M、W、C、F、A、Q、G、P、S、K、W、またはRである、請求項1~5のいずれか1項に記載のAAVカプシドタンパク質。
[請求項7]
配列番号8として特定されるAAV8の参照アミノ酸配列に基づいて天然のAAV8カプシドタンパク質のアミノ酸位661~670(VP1番号付け)に対応し、配列番号26として特定されるAAV9の参照アミノ酸配列に基づいて天然のAAV9カプシドタンパク質のアミノ酸位659~668(VP1番号付け)に対応するアミノ酸に、または他の任意のAAV血清型のカプシドタンパク質における等価なアミノ酸位に、アミノ酸配列:VGTFNEAKLH(h1;配列番号166)、VSTFNPAKLM(h9;配列番号167)、PLTFNCCKLN(d5;配列番号168)、PVTFNQDKLW(d4;配列番号169)、PVTFNSGKLC(h6;配列番号170)、IGTFNGQKLC(h4;配列番号171)、QVTFNGGKLF(h5;配列番号172)、PGTFNGGKLW(h3;配列番号173)、PGTFNGGKLA(h8;配列番号174)、PGTFNRGKLQ(h7;配列番号175)、PGTFNDGKLG(d6;配列番号176)、PSTFNCMKLP(h2;配列番号177)、PSTFNCPKLQ(h11;配列番号178)、PSTFNLGKLS(d1;配列番号179)、PSTFNGGKLP(d7;配列番号180)、SCTFNLHKLC(h12;配列番号181)、QDTFNRTKLC(h10;配列番号182)、PTTFNRTKLM(d3;配列番号183)、FVTFNGDKLM(xx4;配列番号184)、RRTFNSRKLK(xx2;配列番号185)、SVTFNSAKLQ(e2;配列番号186)、VLTFNGSKLA(e1;配列番号187)、PTTFNPSKLW(xx3;配列番号188)、PVTFNEGKLF(e3;配列番号189)、PTTFNQGKLQ(e5;配列番号190)、PGTFNGGKLG(xx1;配列番号191)、PLTFNNGKLS(xx5;配列番号192)、RSTFNGDKLN(hi-C;配列番号193)、PTTFNVDKLG(hi-A;配列番号194)、PITFNEPKLA(hi-B;配列番号195)、またはWPTFNAGKLR(hi-e;配列番号196)を生じる置換を含むアデノ随伴ウイルス(AAV)カプシドタンパク質。
[請求項8]
前記置換がRSTFNGDKLN(hi-C;配列番号193)である、請求項7に記載のAAVカプシドタンパク質。
[請求項9]
配列番号8として特定されるAAV8の参照アミノ酸配列に基づいて天然のAAV8カプシドタンパク質のアミノ酸位661~667(VP1番号付け)に対応し、配列番号26として特定されるAAV9の参照アミノ酸配列に基づいて天然のAAV9カプシドタンパク質のアミノ酸位659~665(VP1番号付け)に対応するアミノ酸に、または他の任意のAAV血清型のカプシドタンパク質において等価なアミノ酸位に、アミノ酸配列:X1-X2-T-F-N-X3-X4(配列番号198)を生じる置換を含むAAVカプシドタンパク質であって、
X1はP以外の任意のアミノ酸であり;
X2はT以外の任意のアミノ酸であり;
X3はQ以外の任意のアミノ酸であり;および/または
X4はS以外の任意のアミノ酸である
AAVカプシドタンパク質。
[請求項10]
X1のうちの少なくとも1つがRであり、X2がSであり、X3がGであり、および/またはX4がDである、請求項9に記載のAAVカプシドタンパク質。
[請求項11]
X1がRであり、X2がSであり、X3がGであり、およびX4がDである、請求項9に記載のAAVカプシドタンパク質。
[請求項12]
改変5回領域を含み、前記改変5回領域が1つまたは複数のアミノ酸置換を含む、組換えアデノ随伴ウイルス(rAAV)カプシドタンパク質。
[請求項13]
前記rAAVカプシドタンパク質の前記改変5回領域における前記1つまたは複数のアミノ酸置換により、改変5回領域のないカプシドタンパク質を含むAAV粒子と比べて、中和抗体に対する反応性が減少しているAAV粒子が生じる、請求項12に記載のrAAVカプシドタンパク質を含むAAV粒子。
[請求項14]
rAAVが血清型1のものであり、前記1つまたは複数のアミノ酸置換が、配列番号18として特定されるAAV1の参照アミノ酸配列に基づいて位置250~258、324~333、371、372、546~550、557、655~674、または716~721(VP1番号付け)にある、請求項12または13のいずれか1項に記載のrAAVカプシドタンパク質。
[請求項15]
rAAVが血清型2のものであり、前記1つまたは複数のアミノ酸置換が、配列番号19として特定されるAAV2の参照アミノ酸配列に基づいて位置250~258、323~332、370、371、545~548、556、655~673、または715~720(VP1番号付け)にある、請求項12または13のいずれか1項に記載のrAAVカプシドタンパク質。
[請求項16]
rAAVが血清型5のものであり、前記1つまたは複数のアミノ酸置換が、配列番号22として特定されるAAV5の参照アミノ酸配列に基づいて位置240~248、314~323、372、373、532~535、546、644~662、または704~709(VP1番号付け)にある、請求項12または13のいずれか1項に記載のrAAVカプシドタンパク質。
[請求項17]
前記中和抗体がAVBである、請求項14~16のいずれか1項に記載のrAAVカプシドタンパク質。
[請求項18]
rAAVが血清型9のものであり、前記1つまたは複数のアミノ酸置換が、配列番号26として特定されるAAV9の参照アミノ酸配列に基づいて位置251~255、264、325~334、または656~674(VP1番号付け)にある、請求項12または13のいずれか1項に記載のrAAVカプシドタンパク質。
[請求項19]
前記中和抗体がCSAL9である、請求項18に記載のrAAVカプシドタンパク質。
[請求項20]
rAAVが血清型8のものであり、前記1つまたは複数のアミノ酸置換が、配列番号25として特定されるAAV8の参照アミノ酸配列に基づいて位置252~266、326~335、658~676または720(VP1番号付け)にある、請求項12または13のいずれか1項に記載のrAAVカプシドタンパク質。
[請求項21]
rAAVが血清型9のものであり、前記1つまたは複数のアミノ酸置換が、配列番号26として特定されるAAV9の参照アミノ酸配列に基づいて位置251~266、325~334、657~673または718(VP1番号付け)にある、請求項12または13に記載のrAAVカプシドタンパク質。
[請求項22]
前記中和抗体がHL2372である、請求項20または21のいずれか1項に記載のrAAVカプシドタンパク質。
[請求項23]
rAAVが血清型5のものであり、前記1つまたは複数のアミノ酸置換が、配列番号22として提供されるAAV5の参照アミノ酸配列に基づいて位置218、240~258、261、263、267、279、331、350、355~360、364、365、377、378、395、429~432、437、450、451、453~456、458、459、530~543、545~548、639、641、642、648~651、653~658、660~662、697~700、または704~712(VP1番号付け)にある、請求項12または13のいずれか1項に記載のrAAVカプシドタンパク質。
[請求項24]
前記中和抗体がADK5aである、請求項23に記載のrAAVカプシドタンパク質。
[請求項25]
rAAVが血清型5のものであり、前記1つまたは複数のアミノ酸置換が、配列番号22として提供されるAAV5の参照アミノ酸配列に基づいて位置241~248、313~319、321、323、355、356、358~362、440~443、446~449、530~548、645~651、653~661、697、698、および704~712(VP1番号付け)にある、請求項12または13に記載のrAAVカプシドタンパク質。
[請求項26]
前記中和抗体がADK5bである、請求項25に記載のrAAVカプシドタンパク質。
[請求項27]
請求項1~26のいずれか1項に記載のAAVカプシドタンパク質を含むAAVカプシド。
[請求項28]
請求項27に記載のAAVカプシドを含むAAVウイルス粒子。
[請求項29]
(a)請求項27に記載のAAVカプシド、および
(b)少なくとも1つの末端反復配列を含む核酸であって、前記AAVカプシドによりカプセル化されている核酸
を含むウイルスベクター。
[請求項30]
前記核酸が、治療タンパク質または治療RNAをコードする配列を含む、請求項29に記載のウイルスベクター。
[請求項31]
前記ウイルスベクターが、その親AAV血清型とは免疫学的に異なっており、前記親血清型に結合する抗体により認識されない、請求項29に記載のウイルスベクター。
[請求項32]
請求項1~26のいずれか1項に記載のAAVカプシドタンパク質、請求項27に記載のAAVカプシド、請求項28に記載のAAVウイルス粒子、および/または請求項29~31に記載のウイルスベクターを、薬学的に許容される担体中に含む組成物。
[請求項33]
細胞に核酸を投与する方法であって、前記細胞を、請求項29~31のいずれか1項に記載のウイルスベクターまたは請求項32に記載の組成物に接触させるステップを含む方法。
[請求項34]
核酸を対象に送達する方法であって、請求項25もしくは26に記載のウイルスベクターまたは請求項27に記載の組成物を前記対象に投与するステップを含む方法。
[請求項35]
前記対象がヒト対象である、請求項34に記載の方法。
AAV1カプシドタンパク質(ジェンバンク受託番号AAD27757)(配列番号1)
Claims (11)
- 配列番号8として特定されるAAV8の参照アミノ酸配列に基づいて天然のAAV8カプシドタンパク質のアミノ酸位661~670(VP1番号付け)に対応するアミノ酸位に、PGTFNGGKLG(xx1;配列番号191)、RSTFNGDKLN(hi-C;配列番号193)、または、PTTFNVDKLG(hi-A;配列番号194)を生じる置換を含むアデノ随伴ウイルス(AAV)カプシドタンパク質。
- 前記置換がRSTFNGDKLN(hi-C;配列番号193)である、請求項1に記載のAAVカプシドタンパク質。
- 請求項1または2に記載のAAVカプシドタンパク質を含むAAVカプシド。
- 請求項3に記載のAAVカプシドを含むAAVウイルス粒子。
- (a)請求項3に記載のAAVカプシド、および
(b)少なくとも1つの末端反復配列を含む核酸であって、前記AAVカプシドによりカプセル化されている核酸
を含むウイルスベクター。 - 前記核酸が、治療タンパク質または治療RNAをコードする配列を含む、請求項5に記載のウイルスベクター。
- 前記ウイルスベクターが、その親AAV血清型とは免疫学的に異なっており、前記親血清型に結合する抗体により認識されない、請求項5に記載のウイルスベクター。
- 請求項1または2に記載のAAVカプシドタンパク質、請求項3に記載のAAVカプシド、請求項4に記載のAAVウイルス粒子、または請求項5~7のいずれか1項に記載のウイルスベクターを、薬学的に許容される担体中に含む組成物。
- 細胞を、請求項5~7のいずれか1項に記載のウイルスベクターまたは請求項8に記載の組成物に接触させるステップを含む細胞に核酸を投与する方法において使用するための、請求項5~7のいずれか1項に記載のウイルスベクターまたは請求項8に記載の組成物。
- 請求項5~7のいずれか1項に記載のウイルスベクターまたは請求項8に記載の組成物を対象に投与するステップを含む核酸を対象に送達する方法において使用するための、請求項5~7のいずれか1項に記載のウイルスベクターまたは請求項8に記載の組成物。
- 前記対象がヒト対象である、請求項10に記載のウイルスベクターまたは組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023195330A JP2024026105A (ja) | 2018-02-28 | 2023-11-16 | 抗体回避ウイルスベクターのための方法および組成物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862636598P | 2018-02-28 | 2018-02-28 | |
US62/636,598 | 2018-02-28 | ||
US201862687583P | 2018-06-20 | 2018-06-20 | |
US62/687,583 | 2018-06-20 | ||
PCT/US2019/020053 WO2019169132A1 (en) | 2018-02-28 | 2019-02-28 | Methods and compositions for antibody-evading virus vectors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023195330A Division JP2024026105A (ja) | 2018-02-28 | 2023-11-16 | 抗体回避ウイルスベクターのための方法および組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021516044A JP2021516044A (ja) | 2021-07-01 |
JP7393766B2 true JP7393766B2 (ja) | 2023-12-07 |
Family
ID=67805128
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020545088A Active JP7393766B2 (ja) | 2018-02-28 | 2019-02-28 | 抗体回避ウイルスベクターのための方法および組成物 |
JP2023195330A Pending JP2024026105A (ja) | 2018-02-28 | 2023-11-16 | 抗体回避ウイルスベクターのための方法および組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023195330A Pending JP2024026105A (ja) | 2018-02-28 | 2023-11-16 | 抗体回避ウイルスベクターのための方法および組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230242938A1 (ja) |
EP (1) | EP3759218A4 (ja) |
JP (2) | JP7393766B2 (ja) |
CN (1) | CN112041442A (ja) |
AU (1) | AU2019227896A1 (ja) |
BR (1) | BR112020016699A2 (ja) |
CA (1) | CA3092107A1 (ja) |
IL (1) | IL276341A (ja) |
SG (1) | SG11202008278WA (ja) |
WO (1) | WO2019169132A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3356390T3 (pl) | 2015-09-28 | 2021-07-05 | The University Of North Carolina At Chapel Hill | Sposoby i kompozycje dla wektorów wirusowych unikających przeciwciał |
JP7406677B2 (ja) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | 抗体を回避するウイルスベクター |
CA3157700A1 (en) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
WO2021230987A1 (en) | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
CA3184307A1 (en) * | 2020-05-22 | 2021-11-25 | Neuway Pharma Gmbh | Vlp for the treatment of leukodystrophies |
WO2022072888A1 (en) * | 2020-10-01 | 2022-04-07 | Sangamo Therapeutics, Inc. | Methods of detecting anti-aav antibodies |
CN113061625B (zh) * | 2021-04-25 | 2023-04-21 | 华南农业大学 | 一种复制缺陷型犬细小病毒包装载体、复制缺陷型重组犬细小病毒及制备与应用 |
WO2022229703A2 (en) * | 2021-04-30 | 2022-11-03 | Takeda Pharmaceutical Company, Ltd. | New aav8 based immune escaping variants |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017058892A2 (en) | 2015-09-28 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for antibody-evading virus vectors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090215879A1 (en) * | 2008-02-26 | 2009-08-27 | University Of North Carolina At Chapel Hill | Methods and compositions for adeno-associated virus (aav) with hi loop mutations |
AU2016235163B2 (en) * | 2015-03-24 | 2022-03-24 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
-
2019
- 2019-02-28 CA CA3092107A patent/CA3092107A1/en active Pending
- 2019-02-28 AU AU2019227896A patent/AU2019227896A1/en active Pending
- 2019-02-28 JP JP2020545088A patent/JP7393766B2/ja active Active
- 2019-02-28 US US16/976,408 patent/US20230242938A1/en active Pending
- 2019-02-28 SG SG11202008278WA patent/SG11202008278WA/en unknown
- 2019-02-28 WO PCT/US2019/020053 patent/WO2019169132A1/en unknown
- 2019-02-28 CN CN201980028858.XA patent/CN112041442A/zh active Pending
- 2019-02-28 EP EP19760157.8A patent/EP3759218A4/en active Pending
- 2019-02-28 BR BR112020016699-5A patent/BR112020016699A2/pt unknown
-
2020
- 2020-07-28 IL IL276341A patent/IL276341A/en unknown
-
2023
- 2023-11-16 JP JP2023195330A patent/JP2024026105A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017058892A2 (en) | 2015-09-28 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for antibody-evading virus vectors |
Non-Patent Citations (1)
Title |
---|
PNAS,2017年05月30日,Vol. 114, No. 24,pp. E4812-E4821 |
Also Published As
Publication number | Publication date |
---|---|
IL276341A (en) | 2020-09-30 |
JP2021516044A (ja) | 2021-07-01 |
CN112041442A (zh) | 2020-12-04 |
CA3092107A1 (en) | 2019-09-06 |
JP2024026105A (ja) | 2024-02-28 |
BR112020016699A2 (pt) | 2020-12-15 |
WO2019169132A1 (en) | 2019-09-06 |
AU2019227896A1 (en) | 2020-08-20 |
EP3759218A4 (en) | 2021-12-08 |
EP3759218A1 (en) | 2021-01-06 |
US20230242938A1 (en) | 2023-08-03 |
SG11202008278WA (en) | 2020-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7390693B2 (ja) | 抗体回避性ウイルスベクターのための方法および組成物 | |
JP7393766B2 (ja) | 抗体回避ウイルスベクターのための方法および組成物 | |
JP7291397B2 (ja) | 血管系を通過する遺伝子移入の方法および組成物 | |
JP7406783B2 (ja) | パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質 | |
CN110770346B (zh) | 多倍体腺相关病毒载体及其制备和使用方法 | |
JP5136766B2 (ja) | キメラベクター | |
US7867484B2 (en) | Heparin and heparan sulfate binding chimeric vectors | |
JP7425738B2 (ja) | 眼組織を標的とするウイルスベクター | |
JP7406677B2 (ja) | 抗体を回避するウイルスベクター | |
EP2396343A2 (en) | Modified virus vectors and methods of making and using the same | |
US20210348197A1 (en) | Modified adeno-associated virus 5 capsids and uses thereof | |
CN117535247A (zh) | 合理的多倍体腺相关病毒载体及其制造和使用方法 | |
JP2022551739A (ja) | ニーマン・ピック病c型の治療のためのアデノ随伴ウイルスベクター | |
AU2021224551A1 (en) | AAV capsid-promoter interactions and cell selective gene expression | |
JP2024063058A (ja) | 抗体を回避するウイルスベクター | |
AU2022208037A1 (en) | Aav vectors targeting t-cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230414 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230707 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230810 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231017 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231116 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7393766 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |